Pyrrolo[1,3]benzothiazepine-Based Seroonin and Dopamine Receptor Antagonists. Molecular Modeling, Further Structure-Activity Relationship Studies, and Identification of Novel Atypical Antipsychotic Agents

Journal of Medicinal Chemistry

Volumn 47, Issue 1, 2004, Pages 143-157

  Campiani, Giuseppe ^a,b   Butini, Stefania ^a,b   Fattorusso, Caterina ^a,c   Catalanotti, Bruno ^a,c   Gemma, Sandra ^a,b   Nacci, Vito ^a,b   Morelli, Elena ^a,c   Cagnotto, Alfredo ^d   Mereghetti, Ilario ^d   Mennini, Tiziana ^d   Carli, Miriana ^d   Minetti, Patrizia ^e   Di Cesare, M Assunta ^e   Mastroianni, Domenico ^e   Scafetta, Nazzareno ^e   Galletti, Bruno ^e   Stasi, M Antonietta ^e   Castorina, Massimo ^e   Pacifici, Licia ^e   Vertechy, Mario ^e   Di Serio, Stefano ^e   Ghirardi, Orlando ^e   Tinti, Ornella ^e   Carminati, Paolo ^e   more..

^a Europ Res Ctr Drug Discov/Devmt   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e Sigma Tau SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 9 (4 METHYLPIPERAZIN 1 YL)PYRROLO[2,1 B][1,3]BENZOTHIAZEPINE; 7 CHLORO 9 (4 METHYLPIPERAZIN 1 YL)PYRROLO[2,1 B][1,3]BENZOTHIAZEPINE; 9 (4 METHYLPIPERAZIN 1 YL)PYRROLO[2,1 B][1,3]BENZOTHIAZEPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; LIGAND; OLANZAPINE; PHENCYCLIDINE; PROLACTIN; PYRROLE; SEROTONIN 2A RECEPTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; BINDING AFFINITY; BINDING ASSAY; CATALEPSY; CHEMICAL ANALYSIS; CHEMICAL BOND; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG PURIFICATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; IN VIVO STUDY; MALE; MOLECULAR MODEL; MOUSE; MULTIPLE DRUG DOSE; NONHUMAN; PROLACTIN BLOOD LEVEL; RAT; REACTION ANALYSIS; SCORING SYSTEM; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SUBSTITUTION REACTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BENZOTHIEPINS; CATALEPSY; COGNITION DISORDERS; DOPAMINE ANTAGONISTS; HUMANS; MALE; MICE; MODELS, MOLECULAR; MOTOR ACTIVITY; PITUITARY GLAND, ANTERIOR; PROLACTIN; PYRROLES; RATS; RATS, INBRED F344; RATS, WISTAR; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, SEROTONIN, 5-HT2; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZEPINES;

EID: 9144232388     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0309811     Document Type: Article

References (60)

1. Work Group on Schizophrenia. Practice guidelines for the treatment of patients with schizophrenia. Am. J. Psychiatry 1997, 153, 1-63
2. Wickelgren, I.A route to treating schizophrenia? Science 1998, 281, 1264-1265.
3. (b) Harrison, P. J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999, 122, 593-624.
4. Carlsson, A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988, 1, 179-186.
5. Meltzer, H. Y. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989, 99, S18-S27.
6. Campbell, M.; Young, P. I.; Bateman, D. N. The use of atypical antipsychotics in the menagement of schizophrenia. Br. J. Pharmacol. 1999, 47, 13-22.
7. Richelson, E. Receptor pharmacology of neuroleptics: relation to clinical effects. J. Clin. Psychiatry 1999, 60, 5-14.
8. Kelleher, J. P.; Centorrino, F.; Albert, M. J.; Baldessarrini, R. J. Advances in atypical antipsychotics for the treatment of schizophrenia. CNS Drugs 2002, 16, 249-261.
9. Tollefson, G. D.; Kuntz, A. J. Review of recent clinical studies with olanzapine. Br. J. Psychiatry 1999, 174, 30-35.
10. (b) Bhana, N.; Perry, M. C. Olanzapine. A review of its use in the treatment of bipolar I disorder. CNS Drugs 2001, 15, 871-904.
11. Gardner, I.; Zahid, N.; McCrimmon, D.; Uetrecht J. P. A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes.Mol. Pharmacol. 1998, 53, 991-998.
12. (b) Gardner, I.; Leeder, J. S.; Chin, T.; Zahid, N.; Uetrecht, J. P. A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. Mol. Pharmacol. 1998, 53, 999-1008.
13. Koller, E. A.; Doraiswamy, P. M. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002, 22, 841-852.
14. Geddes, J.; Freemantle, N.; Harrison, P.; Bebbington, P. Atypical antipsychatics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br. Med. J. 2000, 321, 1371-1376.
15. http://www.abpi.org.uk/publications/publication-details/ targetSchizophrenia/section5-asp.
16. Campiani, G.; Butini, S.; Gemma, S.; Nacci, V.; Fattorusso, C.; Catalanotti, B.; Giorgi, G.; Cagnotto, A.; Goegan, M.; Mennini, T.; Minetti, P. ; Di Cesare, M. A.; Mastroianni, D.; Scafetta, N.; Galletti, B.; Stasi, M. A.; Castorina, M.; Pacifici, L.; Ghirardi, O.; Tinti, O.; Carminati, P. Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. J. Med. Chem. 2002, 45, 344-359.
17. Campiani, G.; Nacci, V.; Bechelli, S.; Ciani, S. M.; Garofalo, A.; Fiorini, I.; Wikstrom, H.; de Boer, P.; Liao, Y.; Tepper, P. G.; Cagnotto, A.; Mennini, T. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo-[2,1-b][1,3]benzothiazepine structure. J. Med. Chem. 1998, 41, 3763-3772.
18. 2c receptors. Br. J. Pharmacol. 1995, 115, 622-628.
19. 2 dopamine receptor. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 9762-9766.
20. (d) Dini S.; Caselli, G. F.; Ferrari, M. P.; Giani, R.; Clavenna, G. Heterogenity of [3H]-mepyramine binding sites in guinea pig cerebellum and lung. Agents Actions 1991, 33, 181-184.
21. 1A-receptor agonist. J. Med. Chem. 1993, 36, 2059-2065.
22. Haigh, D.; Jelfcott, L. J.; Magee, K.; McNab, H.; J.Chem. Soc. Perk. Trans. 1 1996, 52, 2895-2900;
23. A. J. Phillips, Y. Uto, P. Wipf, M. J. Reno, D. R. Williams, Org. Lett. 2000, 2, 1165-1168.
24. 2 antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles. J. Med. Chem. 1992, 35, 1092-1101.
25. 2-antagonistic activity. J. Med. Chem. 1988, 31, 2247-2256.
26. Caglioti, L. Org. Synth. 1972, 52, 122-124.
27. Ornstein, P. L.; Schoepp, D. D.; Arnold, M. B.; Leander, J. D.; Lodge, D.; Paschal, J. W.; Elzey, T. 4-(Tetrazolylalkyl)piperidine-2-carboxylic acids. Potent and selective N-methyl-D-aspartic acid receptor antagonists with a short duration of action. J. Med. Chem. 1991, 34, 90-97.
28. Coffen, D. L.; Fryer, R. I.; Katonak, D. A.; Wong, F. Quinazolines and 1,4-benzodiazepines. LXX. v-Triazolo[1,5-a][1,4]benzodiazepines. J. Org. Chem. 1975, 40, 894-897.
29. Meltzer, H. Y.; Matsubara, S.; Lee, J.-C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pki values. J. Pharmacol. Exp. Ther. 1989, 251, 238-246.
30. 1 adrenoceptor antagonists. Conformationally flexible analogues of the atypical antipsychotic sertindole. J. Med. Chem. 1996, 39, 3723-3738.
31. 2 antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles. J. Med. Chem. 1992, 35, 1092-1101.
32. Froimowitz, M.; Rämsby, S. Conformational properties of semirigid antipsychotic drugs: the pharmacophore for dopamine D-2 antagonist activity. J. Med. Chem. 1991, 34, 1707-1714.
33. Liljefors, T.; Bøgesø, K. P. Conformational analysis and structural comparisons of (1R,3S)-(+)- and (1S,3R)-(-)-tefludazine, (S)-(+)- and (R)-(-)-octoclothepin, and (+)-dexclamol in relation to dopamine receptor antagonism and amine-uptake inhibition. J. Med. Chem. 1988, 31, 306-312.
34. 2 receptor antagonists. J. Med. Chem. 1991, 34, 2023-2030.
35. 2 receptors. J. Med. Chem. 1994, 37, 950-962.
36. Phillips, S. T.; Paulis, T.; Neergaard, J. R.; Baron, B. M.; Seigel, B. W.; Seeman, P.; Van Tol, H. H. M.; Guan, H.; and Smith, H. E. Binding of 5H-Dibenzo[a,d]cycloheptene and 5H-Dibenz[b,f]-oxepine analogues of clozapine to dopamine and serotonin receptors. J. Med. Chem. 1995, 38, 708-714.
37. 2 affinity results in the loss of Clozapine's atypical antipsychotic action. Neuroreport 2002, 13, 831-835.
38. Irrure, J.; Narbon, E.; Serra, B.; Teixido, J. Conformational barrier calculation of dibenzo[b,e]azepine derivatives by semiempirical method AM1. In QSAR and Molecular Modeling: Concepts, Computational Tools and Biological Applications; Prous Science Publisher: Barcelona, 1995; pp 329-331.
39. Randall, W. C., Anderson, P. S., Cresson, E. L., Hunt, C. A., Thomas F. Lyon, Rittle, K. E., Remy, D. C., Springer, J. P., Hirshfield, J. M., Hoogsteen, K., Williams, M., Risley, E. A., Totaro J. A. Synthesis, assignment of absolute configuration, and receptor binding studies relevant to the neuroleptic activities of a series of chiral 3-substituted Cyproheptadine atropisomers. J. Med. Chem. 1979, 22, 1222-1230.
40. Lieberman, J. A.; Mailman, R. B.; Buncan, G.; Sikich, L.; Chakos, M.; Nichols, D. E.; Kraus, J. E. A decade of serotonin research: role of serotonin in treatment of psychosis. Serotoninergic basis of antipsychotic drug effects in schizophrenia. Biol. Psychiatry 1998, 44, 1099-1117.
41. Abi-dargham, A.; Laruelle, M.; Charney, D.; Krystal, J.The role of serotonin in pathophisiology and treatment of schizophrenia. J. Neuropsychiatry 1997, 9, 1-17.
42. 2 dopamine receptor blockade. J. Pharm. Exp. Ther. 1991, 253, 1162-1170.
43. 2C receptor subtypes and significance of the haloperidol dose used. Neuropharmacology 2000, 39, 1053-1063.
44. Lucas, G.; De Deurwardáre, P.; Porras, G.; Spampinato, U. Endogenous serotonin enhances the release of dopamine in the striatum only when nigro-striatal dopaminergic transmission is activated. Neuropharmacology 2000, 39, 1984-1995.
45. 2B2C receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J. Neurochem. 1999, 73 (2), 1033-1042.
46. Di Giovanni, G.; De Deurwardáre, P.; Di Mascio, M.; Di Matteo, V. ; Esposito, E.; Spampinato, U. Selective blockade of serotonin-2C2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neurosci. 1999, 91 (2), 587-597.
47. Lucas, G.; Spampinato, U. Role of striatal serotonin 2A and serotonin 2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J. Neurochem. 2000, 74, 693-701.
48. 2 adrenoceptor blockade. Science 1999, 286, 105-107.
49. (b) Lindström, L. H. Schizophrenia, the dopamine hypothesis and α2-adrenoceptor antagonists. Trends Pharmacol. Sci. 2000, 21, 198-199.
50. Gudelsky, G. A.; Koening, J. I.; Simonovic, M.; Koiama, T.; Ohmori, T.; Meltzer, H. Y. Differential effects of haloperidol, clozapine and fluperlapine on tuberoinfundibular dopamine neurons and prolactin secretion in the rat. J. Neurol. Transm. 1987, 68, 227-240.
51. De Lean, K. W.; Munson, P. J.; Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay and phisiological dose-response curves. Am. J. Physiol. 1978, 235, E97-E102.
52. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
53. Costall, B.; Naylor, R. J.; Nohria, V. Climbing behavior induced by apomorphine in mice: a potential model for detection of neuroleptic activity. Eur. J. Pharmacol. 1978, 50, 39-50.
54. Rigdon, G. C.; Norman, M. H.; Cooper, B.B.; Howard, J. L.; Boncek, V. M. ; Faison, W. L.; Nanry, K. P.; Pollard, G. T. 1192U90 in animal tests that predict antipsychotic efficacy, anxiolysis, and extrapyramidal side effects. Neuropsychopharmacology 1996, 15, 231-242.
55. Moore, N. A.; Tye, N. C.; Axton, M. S.; Risius, F. C. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J. Pharmacol. Exp. Ther. 1992, 262, 545-551.
56. Carli, M.; Robbins, T. W.; Evenden, J. L.; Everitt, B. J. Effects of lesions to ascendine noradrenergic neurons on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behav. Brain Res. 1983, 9, 361-380.
57. Maple, J. R., Diniur, U., Hagler, A. T. Derivation of force fields for molecular mechanics and dynamics from ab initio energy surfaces. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 5350-5354.
58. (b) Dauber-Osguthorpe, P.; Roberts, V. A.; Osguthorpe, D. J.; Wolff, J.; Genest, M.; Hagler, A. T. Structure and energetics of ligand binding to proteins. Proteins: Struct., Function Genet. 1988, 4, 31-47.
59. Fletcher, R. Unconstrained Optimization. In Pratical Methods of Optimization; John Wiley & Sons: New York, 1980; Vol. 1.
60. Stewart, J. J. P. MOPAC: A Semiempirical Molecular Orbital Program J. Comput.-Aided Mol. Des. 1990, 4, 1-105.